CL2022003725A1 - Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity. - Google Patents
Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity.Info
- Publication number
- CL2022003725A1 CL2022003725A1 CL2022003725A CL2022003725A CL2022003725A1 CL 2022003725 A1 CL2022003725 A1 CL 2022003725A1 CL 2022003725 A CL2022003725 A CL 2022003725A CL 2022003725 A CL2022003725 A CL 2022003725A CL 2022003725 A1 CL2022003725 A1 CL 2022003725A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- activity
- diseases associated
- aberrant
- interleukin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
Abstract
La presente invención se refiere a la medicina y se refiere al tratamiento de enfermedades asociadas con la actividad aberrante de la interleucina-6 y el desarrollo del síndrome de liberación de citocinas (tormenta de citocinas), preferentemente el tratamiento de COVID-19, así como otras enfermedades complicadas por la actividad aberrante de interleucina-6 y el desarrollo del síndrome de liberación de citocinas, utilizando el compuesto 1-(2-(1-metil-1Himidazol-4-il)etil)piperidina-2,6-diona (fórmula I). La invención proporciona la creación de un nuevo fármaco eficaz para el tratamiento de enfermedades asociadas con el desarrollo del síndrome de liberación de citocinas.The present invention relates to medicine and concerns the treatment of diseases associated with aberrant interleukin-6 activity and the development of cytokine release syndrome (cytokine storm), preferably the treatment of COVID-19, as well as other diseases complicated by aberrant interleukin-6 activity and the development of cytokine release syndrome, using the compound 1-(2-(1-methyl-1Himidazol-4-yl)ethyl)piperidine-2,6-dione ( formula I). The invention provides for the creation of a new effective drug for the treatment of diseases associated with the development of cytokine release syndrome.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2020121363A RU2774928C2 (en) | 2020-06-26 | Use of glutarimide derivative for therapy of diseases associated with aberrant activity of interleukin-6 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022003725A1 true CL2022003725A1 (en) | 2023-05-19 |
Family
ID=79281595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022003725A CL2022003725A1 (en) | 2020-06-26 | 2022-12-22 | Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity. |
Country Status (6)
Country | Link |
---|---|
CN (1) | CN115803026A (en) |
BR (1) | BR112022026356A2 (en) |
CL (1) | CL2022003725A1 (en) |
CO (1) | CO2023000604A2 (en) |
MA (1) | MA58653B1 (en) |
WO (1) | WO2021262040A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023177329A1 (en) * | 2022-03-18 | 2023-09-21 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Use of 1-(2-(1н-imidazole-4-yl)ethyl)piperidine-2,6-dione to treat cough caused by viral infections |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2112716A1 (en) * | 1971-03-17 | 1972-10-05 | Thomae Gmbh Dr K | Biphenylyl-butyric acid derivs. - anti phlogistics |
DE10002509A1 (en) * | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | New substituted glutarimide derivatives are IL-12 antagonists, are useful as immunomodulators and for the treatment of angiopathy, hematological or oncological disorders |
UA115431C2 (en) * | 2011-10-11 | 2017-11-10 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Use of glutaryl histamine to treat respiratory tract infections |
CN102432544B (en) * | 2011-11-17 | 2014-05-21 | 天津医科大学 | 5-substituted benzyl methylene imidazole alkyl-2,4-diketone derivative and application thereof |
EA032951B1 (en) * | 2013-04-12 | 2019-08-30 | Общество С Ограниченной Ответственностью "Рсв Терапевтикс" | Glutarimide derivative, use thereof, pharmaceutical composition based thereon, process for preparing same |
RU2552929C1 (en) * | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Pharmaceutical composition, containing derivatives of glutarimides, and their application for treatment of eosinophilic diseases |
US10739353B2 (en) * | 2014-12-31 | 2020-08-11 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
GEP20227402B (en) * | 2017-09-07 | 2022-08-10 | Valenta Intellekt Ltd | Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines |
AU2021257439A1 (en) * | 2020-04-13 | 2022-12-15 | University Health Network | Methods for treating cytokine release syndrome |
EP4144728A4 (en) * | 2020-04-30 | 2023-08-23 | Shanghaitech University | Heterocycle and glutarimide skeleton-based compound and applications thereof |
-
2021
- 2021-06-18 MA MA58653A patent/MA58653B1/en unknown
- 2021-06-18 BR BR112022026356A patent/BR112022026356A2/en unknown
- 2021-06-18 CN CN202180044905.7A patent/CN115803026A/en active Pending
- 2021-06-18 WO PCT/RU2021/050170 patent/WO2021262040A1/en active Application Filing
-
2022
- 2022-12-22 CL CL2022003725A patent/CL2022003725A1/en unknown
-
2023
- 2023-01-19 CO CONC2023/0000604A patent/CO2023000604A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA58653A1 (en) | 2023-07-31 |
BR112022026356A2 (en) | 2023-01-17 |
RU2020121363A (en) | 2021-12-27 |
MA58653B1 (en) | 2024-02-29 |
WO2021262040A1 (en) | 2021-12-30 |
RU2020121363A3 (en) | 2021-12-27 |
CO2023000604A2 (en) | 2023-01-26 |
CN115803026A (en) | 2023-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022001625A1 (en) | Pyrazolyl derivatives useful as anti-cancer agents | |
UY32462A (en) | NEW BIFENYLL DERIVATIVES FOR HEPATITIS C 644 VIRUS INFECTION TREATMENT | |
PA8635201A1 (en) | USE OF SUBSTITUTED QUINOLINE DERIVATIVES FOR THE TREATMENT OF DRUG RESISTANT MICOBACTERIAL DISEASES | |
CO6960552A2 (en) | Compounds of (hetero) arylcyclopropylamine as inhibitors of lsd1 | |
AR060536A1 (en) | GLUCOCORTICOID RECEPTOR AGONIST AND PHARMACEUTICAL COMPOSITIONS | |
ECSP12011638A (en) | PIRIDINE AND PIRAZINE DERIVATIVES AS PROTEIN KINase MODULATORS | |
ECSP066302A (en) | OMEGA-CARBOXIARIL-DIFENIL-UREA REPLACED WITH FLUORINE FOR THE TREATMENT AND PREVENTION OF DISEASES AND AFFECTIONS | |
AR077975A1 (en) | PIRAZOL PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | |
MA37405A1 (en) | Heterocyclyl compounds | |
UY32483A (en) | NEW BENCIMIDAZOL COMPOUNDS FOR THE TREATMENT OF RESPIRATORY SINCICIAL VIRUS | |
CO6470846A2 (en) | AMINOBUTICAL DERIVATIVES REPLACED AS NEPRILISINE INHIBITORS | |
CL2015002608A1 (en) | Amino-pyrazole compound and related medicinal uses. | |
CO7131360A2 (en) | Novel substituted cyclic n-pyridinyl amides as kinase inhibitors | |
MX2020004283A (en) | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors. | |
UY32574A (en) | CXCR3 RECEIVER ANTAGONISTS | |
CL2022003725A1 (en) | Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity. | |
NI200700032A (en) | ARILSULFONYLESTILBEN DERIVATIVES FOR INSOMNIA TREATMENT AND RELATED AFFECTIONS | |
EA201071039A1 (en) | NEW DERIVATIVES 1-BENZYL-3-HYDROXYMETYLINDASOL AND THEIR APPLICATION FOR THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 And P40 | |
BR112017003242A2 (en) | compound, methods for treating virus infection and for the manufacture of a medicament, pharmaceutical composition, and use of a compound. | |
EA201001857A1 (en) | PHARMACEUTICAL MEDICINE FORM FOR IMMEDIATE RELEASE OF INDOLINON DERIVATIVE | |
UY38144A (en) | INHIBITORS OF SIGNALING MEDIATED BY TYROSINE KINASE | |
UY30916A1 (en) | DERIVATIVES OF 1- [REPLACED] - 3- [REPLACED] -1-AZONA-BICICLO [2,2,2] OCTANO AND ITS ENANTIOMERS | |
EA202091604A1 (en) | INHIBITION OF THE ION CHANNEL A1 WITH A TRANSITOR RECEPTOR POTENTIAL | |
CL2022001337A1 (en) | Pyridopyrimidinone derivatives as ahr antagonists | |
ECSP088257A (en) | AMIDA DERIVATIVES |